ScholarIQanswers from OpenAlex & ORCID
Michaela Mattheus
ResearcherPublications, citations & collaboration network
Michaela Mattheus is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michaela Mattheus have?
ScholarIQindexed works
Michaela Mattheus has 142 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michaela Mattheus have?
ScholarIQcitation count
Michaela Mattheus has 20,334 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michaela Mattheus?
ScholarIQh-index
Michaela Mattheus has an h-index of 33 in OpenAlex.
What is the i10-index of Michaela Mattheus?
ScholarIQi10-index
Michaela Mattheus has an i10-index of 56 in OpenAlex.
What is the ORCID of Michaela Mattheus?
ScholarIQorcid
The ORCID for Michaela Mattheus is on the source record.
What is the OpenAlex record for Michaela Mattheus?
ScholarIQopenalex
The OpenAlex for Michaela Mattheus is on the source record.
What are the most-cited papers on Michaela Mattheus?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen, Bernard Zinman, Mark A. Espeland, Hans J. Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra, Thomas Meinicke, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, Nikolaus Marx, for the CAROLINA Investigators
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, David Fitchett, Michaela Mattheus, Jyothis T. George, Hans J. Woerle, Uli C. Broedl, Maximilian von Eynatten, Bernard Zinman
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z.I. Cherney, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka‐Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner